Antonio Marra, MD, on Clinical Implications of Genomic Instability and Treatment of Advanced Breast Cancer

Posted: Sunday, September 11, 2022

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses the clinical challenges of resistance to endocrine therapy with or without CDK4/6 inhibition in otherwise eligible patients with estrogen receptor–positive/HER2-negative metastatic breast cancer.